Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Why others & not Onc ( yet)…?

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Nov 10, 2024 7:06pm

83 Views

Post# 36305934

RE:RE:RE:Why others & not Onc ( yet)…?

October 04, 2024 - Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path

“Having treated well over 100 HR+/HER2- metastatic breast cancer patients in multiple clinical studies, these results provide the basis for a development path leading to an accelerated approval."

https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-key-progress-and-upcoming-studies-for-breast-and-pancreatic-cancer-treatments-prepares-for-fda-accelerated-approval-path/

<< Previous

Bullboard Posts

Next >>

E3 inches closer to Alberta's first lithium production plant